Posted: Jul. 24, 2012
It was announced yesterday that Bapineuzumab, the Abeta immunotherapy drug, failed to meet cognitive and functional goals in a late stage trial of Alzheimer's patients who carry the APOE4 variant. “There was no reason to believe, unless there was a miracle, that this would be positive. It will only be the results of the non-APOE4 carriers that will inform us about the future [of bapineuzumab].” said Rudolph Tanzi, Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard Medical School and MGH in Boston and Chair of the Cure Alzheimer’s Research Consortium.
Posted: Jul. 18, 2012
Cure Alzheimer’s Fund is pleased to salute Massachusetts General Hospital for placing number 1 in the current issue of U.S. News and World Report’s “Best Hospital” survey. While Cure Alzheimer’s Fund has supported more than 24 leading Alzheimer’s research institutions since its inception in 2004, Mass General has received almost $10 million in research grants from Cure Alzheimer’s Fund during that time.
Posted: Jul. 12, 2012
Genes are the specific DNA blueprints for life, and all genes play roles that are essential for health. But some can carry DNA variants that influence risk for disease, either by increasing or decreasing susceptibility. If a variation in a gene is very rare, it’s called a mutation. The mutation may cause disease, increase risk for a disease, protect against a disease, or have no impact on health at all.
Posted: Jun. 8, 2012
The New York Times Magazine appearing on Sunday, June 10, 2012, and available now online, carries a powerful narrative of a family’s journey through the tragedy of early-onset Alzheimer’s. It is a great contribution to Alzheimer’s awareness and the need for more research to end this disease, and a reinforcement of the priorities that the director of the National Institutes of Health has put on genetic research into the origins of Alzheimer’s.
Posted: Jun. 6, 2012
Dr. Cathy Greenblat hasn’t always been a photographer, but she has always followed her heart. Before taking early retirement from Rutgers University, where she was a sociology professor for 35 years, she took a sabbatical in the spring of 2001 and made a decision that ultimately would change her life.
Posted: Jun. 6, 2012
Alzheimer’s research for many years has been dominated by a focus on Abeta “plaques,” a focus that largely has overlooked the other infamous hallmark of the disease—the tau-based neurofibrillary “tangles.” The research world recently has broadened its scope to include significant research into tau.
Posted: Jun. 4, 2012
Bobby Zerwick left his comfortable home in Pennsylvania last March 10 with two goals: To hike the entire Appalachian Trail this summer and to raise much-needed research funds to find a cure for Alzheimer’s disease. The hike started at Springer Mountain in Georgia, and Bobby will hike north for a total of about five months. His journey will be completed this late summer or early fall when he reaches Mount Katahdin in Maine, having traveled more than 2,175 miles.
Posted: May 22, 2012
THE COMING ALZHEIMER’S TSUNAMI: Society’s Next Big Challenge
Given the worldwide concern about Alzheimer’s disease, Mr. Kalyan Banerjee, president of Rotary International, invited Cure Alzheimer’s Fund to present at the Rotary Club’s Annual Conference in Bangkok, Thailand, on May 9, 2012.
© 2005-2014 Cure Alzheimer's Fund. All rights reserved.